The global next-generation sequencing library preparation market size is estimated at USD 1.42 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 13.16% from 2023 to 2030. The library preparation market is witnessing growth due to the factors such as a rise in sequencing and increasing awareness of genomics among healthcare professionals. Additionally, there have been more research and development projects utilizing NGS technologies, a rise in the use of NGS for clinical diagnostics, and applications for discovery that require NGS technology are some of the factors driving the market growth.
The COVID-19 pandemic has positively impacted the demand for next-generation sequencing which ultimately boost the library preparation workflow. The NGS technology has significantly helped the acceleration of diagnostic processes during the pandemic by effective screening and detection of the SARS‐CoV‐2 virus mutations at the nucleotide level. This helped the researchers to develop preventive measures for the spread of new strains. Moreover, many NGS-based COVID-19 diagnostic tests secured regulatory approvals. For instance, in June 2020, Illumina, Inc. secured the U.S. FDA emergency use authorization for Illumina’s NGS based COVIDSeq diagnostic test for COVID-19 which helped to drastically increase the rate of diagnostics.
The increasing prevalence of genetic disorders across the globe is expected to boost the library preparation market growth in the coming years. According to WHO, 10 out of 1000 births are diagnosed with a single gene disease. NGS is predominantly of use for diagnostics in dealing with genetic disorders. Therefore, this is a strong market driver for the utility of NGS and so its library preparation. For instance, in May 2022, Genes2Me launches wide variety of NGS panels for oncology and hereditary diseases for most comprehensive analysis using platforms like Illumina, Thermo Fisher ION, and so on.
Many comprehensive NGS libraries are prepared to be used for the analysis of specific disease conditions and to be able to screen for a wide spectrum of genetic disorders including rare diseases and cancers. Library preparation is expected to emerge with substantial market space due to its reliable outcomes. For instance, in March 2022, Illumina launched NGS based TruSight Oncology Comprehensive test that can capably assess a several tumor genes. Its biomarkers are able to derive a specific individual’s molecular profile. The test is used for the evaluation of unique genomic signatures, such as tumor-mutational burden and micro-satellite instability.
Moreover, market players have been actively undertaking various initiatives to support the demand for precise NGS-based solutions. For instance, Element Biosciences, Inc., declared the use of Roche KAPA HyperPlus and KAPA EvoPlus library preparation and target enrichment kits in their whole-genome, and whole-exome sequencing applications. Moreover, in December 2021, Roche launched the AVENIO Edge pre-analytical platform for advancement of sequencing technologies to deliver a fully-automated and comprehensive sequencing solutions.
The targeted sequencing held the largest share in 2022. Targeted sequencing using facilitates robust detection of commonly occurring and rare genetic variations that may be causative of a disease condition. It is also used for the detection of genetic aberrations that are contributive to therapeutic drug response and adverse effects in an individual. The growing global incidence of diseases and genetic disorders including cancers are contributing to the growth of the segment.
The WGS segment is anticipated to grow significantly during the forecast period. Lowered sequencing costs and analysis of genome-wide characteristics make whole-genome sequencing a powerful tool for genomics research. It is a comprehensive technique that is used for analysis of entire genome for detailed inference of inherited disorders, characterizing mutations and to trace disease outbreaks. For instance, In December 2021, PacBio signed into a collaboration with researchers at UCLA for advanced identification of the causes of rare diseases. The collaboration is intended to leverage PacBio’s Hi-Fi long-read sequencing technology for WGS to analyze undiagnosed pediatric rare diseases.
The reagents & consumables held the largest share of 77.19% in 2022. NGS library preparation includes the construction of DNA and RNA sequence libraries, amplification, and quantification. Many players are collaboratively working towards the construction of specific libraries to yield the most favorable outcomes from sequencing, using appropriate laboratory reagents. For instance, in January 2022, Singular Genomics Systems, Inc. signed into a collaboration with Watchmaker Genomics to aid researchers and clinicians to validate its Watchmaker-DNA library preparation kits to be used with the G4 sequencing platform using NGS and multiomics technologies.
The instrument segment is anticipated to show a significant market share in 2022. The ability to produce huge data with sequencing makes WGS a powerful tool for genomics research. Moreover, the introduction of advanced and novel sequencing instruments boosted segment growth. For instance, in December 2022, Singular Genomics introduced the G4 Sequencing platform. This novel platform will offer adjustable run capacity and up to three times the data output per hour of existing benchtop instruments.
The drug & biomarker discovery held the largest share of 62.17% in 2022. Many companies are collaboratively working towards construction of precise NGS libraries yield most favorable outcomes from sequencing, using appropriate laboratory reagents. For instance, in September 2022, QIAGEN entered into a collaboration with Neuron23 for the development of NGS-based companion diagnostics using Neuron23’s proprietary molecule, leucine-rich repeat kinase inhibitor which is a brain penetrant used for the treatment of Parkinson’s disease. Qiagen will develop and validate a clinical trial assay that will essentially identify the combination of biomarkers identified by Neuron23 along with comprehensive support for drug development.
The disease diagnostics segment is anticipated to grow significantly during the forecast period. NGS reliably sequences all genes that are relevant to a given phenotype to precisely detect the causative contribution to a disease condition. Moreover, NGS performs simultaneous analysis of multiple genes potentially saving time, money, and tissue if many potential markers are needed to be analyzed for a disease. For instance, in November 2022, Illumina Inc. declares the release of a novel NGS-based diagnostic test for the identification of genito-urinary pathogens and antimicrobial resistance using precision metagenomics for the detection and quantification of over 170 pathogens and more than 3700 markers associated with 18 different drug classes.
The academics & research institutions segment held the highest market share in 2022. NGS based high-throughput sequencing technologies have been extensively applied in specific research activities like gene-expression profiling, chromatin immune-precipitation and small-RNA sequencing to enhance the outcomes of biological and biomedical research. For instance, in March 2021, researchers at the University of California signed into a collaboration with Miroculus, Inc., and Purigen Biosystems, for the development of a revolutionary tool for personal lab automation for the optimization of an automated PCR-free Whole Genome Sequencing library preparation workflow with micro-input human samples.
The Hospital & Clinics segment is anticipated to grow significantly during the forecast period owing to the rising incidence of cancer, genetic disorders, and rare diseases across the globe. According to the Centre for Disease Control (CDC), NGS has transitioned from research to clinical use in the past 5 years. Genome sequencing analysis is a preferred diagnostic step because its outcomes offer insights into the characteristic contribution of genes to cause a given disease condition.
North America leads the global NGS library preparation market with a share of 48.96% in 2022. The growth of the market in the region is mainly attributed to extensive disease-based research studies sponsored by academic research institutes and pharmaceutical giants. For instance, in March 2021, Swift Biosciences signed into a collaboration with SPT Labtech for enhancement of Swift Biosciences' library preparation kits on mosquito genomics and dragonfly discovery platforms, so as to expand the portfolio of library preparation solutions for degraded DNA, low input RNA and custom amplicon panels.
The Asia Pacific is expected to grow considerably in the future due to the rising prevalence of rare diseases and high population density. Moreover, key market players are working towards entering the Asia Pacific market with their NGS library preparation expertise. For instance, in May 2021, BGI signed into an agreement with Ethiopian Biotechnology Institute to carryout pilot scale testing of HPV genotyping to establish a novel technique for HPV screening, diagnosis, and treatment.
Key players operating in the market are focusing on partnerships, strategic collaborations, and geographical expansion, in emerging and economically favorable regions. For instance, in August 2020, Beckman Coulter Inc. signed into a collaboration with Fry Laboratories LLC., and BioID Genomics Inc., for the development of a rapid NGS-based diagnostics technology, to be used for the detection of COVID-19. The collaboration was intended to integrate Beckman Coulter’s capabilities in automation with Fry Laboratories’ NGS library preparation expertise.
Agilent Technologies, Inc.
Integrated DNA Technologies
F. Hoffmann-La Roche AG, Inc.
Beckman Coulter Inc. (Danaher Corporation)
Dickinson and Company
New England Biolabs Inc.
Pacific Biosciences of California, Inc.
Thermo Fisher Scientific Inc.
Tecan Group Ltd.
Market size value in 2023
USD 1,591.87 million
Revenue forecast in 2030
USD 3.78 billion
CAGR of 13.16% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Sequencing type, Product, Application, End-use, Region
North America; Europe; Asia Pacific; Latin America; MEA
U.S., Canada, U.K., Germany, Spain, Italy, France, Russia, Japan, China; India, South Korea, Australia, Brazil, Mexico; Argentina; South Africa, Saudi Arabia; UAE
Key companies profiled
Agilent Technologies, Inc., Integrated DNA Technologies, F. Hoffmann-La Roche AG, Inc., Illumina, Inc., Beckman Coulter Inc. (now part of Danaher Corporation), Becton, Merck KGaA, Dickinson and Company, New England Biolabs, Inc., PerkinElmer Inc., QIAGEN N.V., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Tecan Group Ltd.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the NGS library preparation market based on sequencing type, product, application, end-use, and region
Sequencing Type Outlook (Revenue, USD Million, 2018 - 2030)
Targeted Genome Sequencing
Whole Genome Sequencing
Whole Exome Sequencing
Other Sequencing Types
Products Outlook (Revenue, USD Million, 2018 - 2030)
Reagents & Consumables
DNA Library Preparation Kits
Library Preparation Kits
RNA Library Preparation Kits
Other Reagents & Consumables
Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug & Biomarker Discovery
Reproductive Health Diagnostics
Infectious Disease Diagnostics
Other Disease Diagnostic Applications
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals and Clinics
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa (MEA)
b. The global next-generation sequencing library preparation market size was estimated at USD 1,417.71 million in 2022 and is expected to reach USD 1,591.87 million in 2023.
b. The global next-generation sequencing library preparation market is expected to grow at a compound annual growth rate of 13.16% from 2023 to 2030 to reach USD 3.78 billion by 2030.
b. North America dominated the next-generation sequencing library preparation market with a share of 48.96% in 2022. This is attributable to extensive disease-based research studies sponsored by academic research institutes and pharmaceutical giants.
b. Some key players operating in the next-generation sequencing library preparation market include Agilent Technologies, Inc., Integrated DNA Technologies, F. Hoffmann-La Roche AG, Inc., Illumina, Inc., Beckman Coulter Inc. (now part of Danaher Corporation), Becton, Merck KGaA, Dickinson and Company, New England Biolabs, Inc., PerkinElmer Inc., QIAGEN N.V., Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., and Tecan Group Ltd.
b. Key factors that are driving the market growth include rise in sequencing and increasing awareness of genomics amongst the healthcare professionals. Additionally, there have been more research and development projects utilizing NGS technologies, a rise in the use of NGS for clinical diagnostics, and applications for discovery that require NGS technology
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."